OncoMatch/Clinical Trials/NCT06727773
Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
Is NCT06727773 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Memantine for breast cancer.
Treatment: Memantine — This randomized, placebo-controlled trial aims to assess the feasibility, acceptability, and preliminary efficacy of memantine and the University of Carolina (UNC)'s Get Real \& Heel cancer exercise program (MEM+EX) in addressing cancer-related cognitive impairment (CRCI) and underlying CRCI biomarkers. Ninety stage I-III breast cancer patients with mild cognitive difficulties during chemotherapy will be randomized into three groups: MEM+EX, memantine, or placebo. The study will evaluate recruitment, retention, adherence, acceptability, cognitive function, brain-derived neurotrophic factor (BDNF), inflammatory markers, and frailty at multiple time points.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Required: Stage I, II, III
Prior therapy
Must have received: chemotherapy — neoadjuvant or adjuvant
Completed at least 1 cycle of standard-of-care neoadjuvant or adjuvant chemotherapy
Cannot have received: chemotherapy
Exception: prior to the current regimen
Previous chemotherapy (prior to the current regimen)
Lab requirements
Kidney function
CrCl ≤ 5mL/min [excluded]
Cardiac function
Myocardial infarction in the last 6 months [excluded]
Myocardial infarction in the last 6 months; CrCl ≤ 5mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill · Chapel Hill, North Carolina
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify